Buscar en
Colombian Journal of Anesthesiology
Toda la web
Inicio Colombian Journal of Anesthesiology Metformin-related lactic acidosis: Case report
Información de la revista
Vol. 45. Núm. 4.
Páginas 353-359 (Octubre - Diciembre 2017)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1938
Vol. 45. Núm. 4.
Páginas 353-359 (Octubre - Diciembre 2017)
Case report
DOI: 10.1016/j.rcae.2017.08.010
Open Access
Metformin-related lactic acidosis: Case report
Acidosis láctica por metformina: reporte de caso
Visitas
...
Jesús Salvador Sánchez-Díaza,
Autor para correspondencia
drsalvadorsanchezdiaz@gmail.com

Corresponding author at: Avenida Cuauhtémoc s/n Colonia, Formando Hogar, CP 91897 Veracruz, Veracruz, Mexico.
, Enrique Monares-Zepedab, Enrique Antonio Martínez-Rodríguezc, Jorge Samuel Cortés-Románd, Oscar Torres-Aguilara, Karla Gabriela Peniche-Moguela, Susana Patricia Díaz-Gutiérreza, Eusebio Pin-Gutiérreza, Gerardo Rivera-Solísa, Rosalba Carolina García-Méndeza, Juan Marcelo Huanca-Pacajea, María Verónica Calyeca-Sáncheza
a Centro Médico Nacional “Adolfo Ruiz Cortines”, Instituto Mexicano del Seguro Social (IMSS), Intensive Care Department, Veracruz, Mexico
b Hospital San Ángel Inn Universidad, Mexico City, Mexico
c Medical School, Universidad Veracruzana, Veracruz Campus, Veracruz, Mexico
d Hospital Zambrano Hellion Tec de Monterrey, Monterrey, Mexico
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Tablas (3)
Table 1. Biochemical and haemodynamic variables for hospital admission.
Table 2. Behaviour of the biochemical variables of the patient during slow CRRT and on discharge from the ICU.
Table 3. Aetiologic classification of metabolic acidosis.
Mostrar másMostrar menos
Abstract

Lactic acidosis is defined as the presence of pH <7.35, blood lactate >2.0mmol/L and PaCO2 <42mmHg. However, the definition of severe lactic acidosis is controversial. The primary cause of severe lactic acidosis is shock. Although rare, metformin-related lactic acidosis is associated with a mortality as high as 50%. The treatment for metabolic acidosis, including lactic acidosis, may be specific or general, using sodium bicarbonate, trihydroxyaminomethane, carbicarb or continuous haemodiafiltration. The successful treatment of lactic acidosis depends on the control of the aetiological source. Intermittent or continuous renal replacement therapy is perfectly justified, shock being the argument for deciding which modality to use. We report a case of a male patient presenting with metformin poisoning as a result of attempted suicide, who developed lactic acidosis and multiple organ failure. The critical success factor was treatment with continuous haemodiafiltration.

Keywords:
Acidosis, lactic
Metformin
Sodium bicarbonate
Renal replacement therapy
Lactic acid
Resumen

Definimos acidosis láctica en presencia de pH <7.35, lactato en sangre >2.0mmol/L y PaCO2 <42mmHg. Por otro lado, la definición de acidosis láctica grave es controvertida. La causa principal de acidosis láctica grave es el estado de choque. La acidosis láctica por metformina es rara pero alcanza mortalidad del 50%. La acidosis metabólica incluyendo a la acidosis láctica puede recibir tratamiento específico o tratamiento general con bicarbonato de sodio, trihidroxiaminometano, carbicarb o hemodiafiltración continua. El éxito del tratamiento de la acidosis láctica yace en el control de la fuente etiológica; la terapia de reemplazo renal intermitente o continua está perfectamente justificada, donde el argumento para decidir cuál utilizar será el estado de choque. Presentamos el informe de un caso de un paciente masculino con intoxicación por metformina como intento suicida, quien desarrolló acidosis láctica y falla orgánica múltiple en cuya base para el éxito del caso fue el tratamiento con hemodiafiltración continua.

Palabras clave:
Acidosis láctica
Metformina
Bicarbonato de sodio
Terapia de reemplazo renal
Ácido láctico
Texto completo
Introduction

Lactic acidosis is defined as the presence of pH <7.35, blood lactate >2.0mmol/L and PaCO2 <42mmHg. However, the definition of severe lactic acidosis is controversial. Many physicians associate the severity of lactic acidosis with pH <7.2 or with deleterious effects, mainly haemodynamic, requiring immediate treatment.1–3 The main cause of severe lactic acidosis is shock, associated with a mortality as high as 50% despite adequate aetiological treatment, and 100% when pH is lower than 7.0.4,5

However, an uncommon cause of lactic acidosis is metformin poisoning, with a mortality as high as 50%. The incidence is 3 cases for every 100,000 patients treated per year. The main risk factor for the occurrence of metformin-related lactic acidosis is the renal impairment present in diabetic patients. Voluntary poisoning is rare and its characteristics and prognosis are seldom reported in the literature. It appears that blood levels of metformin are not a determining factor of the outcome in the intoxicated patient, whereas blood lactate >15mmol/L, pH <7.2, organ dysfunction (≥4 points), and lower prothrombin activity (≤50%) are considered risk factors for mortality.6,7 We report the case of a patient intentionally poisoned with metformin who developed multiple organ dysfunction, in whom the critical success factor to resolve the clinical picture was continuous haemodiafiltration.

Clinical case

We present the case of a 74-year-old male patient coming from Veracruz, Mexico, with a history of diabetes mellitus type 2 diagnosed 26 years before, treated with metformin 850mg/day and glibenclamide 10mg/day, a diagnosis of schizophrenia-type psychiatric disorder irregularly treated with olanzapine, and no other relevant history. Following the intentional intake of 20 tablets of metformin, the patient developed a clinical picture characterised by nausea, vomiting and drowsiness, followed 24h later by epistaxis, diaphoresis, and loss of consciousness which prompted transfer for assessment.

Upon arrival to the emergency department, the patient was placed on invasive mechanical ventilation (IMV) because of his neurological condition, and required the use of vasopressors because of haemodynamic instability with altered nodal-type cardiac rhythm. The initial blood work revealed hyperlactatemia (>15mmol/L), hypoglycaemia, hyperkalemia and acute kidney injury (AKI 3) (Table 1).

Table 1.

Biochemical and haemodynamic variables for hospital admission.

BiochemicalHaemodynamic
pH  7.0  Arterial pressure  90/50mmHg 
Lactate  >15mmol/L  Heart rate  50lpm 
HCO3  9.4mEq/L  Norepinephrine  0.4mcg/kg/min 
Urea  72.8mg/dL  Dopamine  0.2mcg/kg/min 
Creatinine  2.9mg/dL  CO  5L/min 
Potassium  6.4mEq/L  CI  2.8L/min/m2 BS 
Glucose  60mg/dL     

pH: negative log of hydrogen ion concentrations; HCO3 bicarbonate; CO: cardiac output; CI: cardiac index; BS: body surface.

Source: Authors.

The patient was admitted to the intensive care unit (ICU) with a diagnosis of severe lactic acidosis secondary to metformin intoxication, an APACHE II score of 25 and a SOFA score of 9. Slow continuous renal replacement therapy (CRRT) was started with haemodiafiltration using a Prisma-Flex® equipment; it was maintained for 48h with an effluent dose of 25ml/kg/h, achieving clinical and laboratory improvement characterised by a reduction in potassium levels, diminished nitrogen compounds, acidosis reversal, and lactate clearance of more than 50% in 24h and 90% at 48h. As a result, the patient was extubated, vasopressors were discontinued, and the patient was discharged from the ICU after 72h (Table 2). The patient gave his consent for the publication of the case report, and approval was also obtained from the hospital's local Ethics Committee.

Table 2.

Behaviour of the biochemical variables of the patient during slow CRRT and on discharge from the ICU.

Variable  244872
pH  7.32  7.31  7.47 
HCO3 (mEq/L)  20.1  20.6  22.6 
Lactate (mmol/L)  7.8  4.5  1.8 
pCO2 (mmHg)  39  41  31 
Base (mmol/L)  −6.0  −5.7  −1.1 
pO2 (mmHg)  111  109  165 
PT (s)  21  19  17.4 
PTT (s)  56  33.2  31.9 
Glucose (mg/dl)  108  160  94 
Urea (mg/dl)  74.9  59.9  42.8 
Creatinine (mg/dl)  2.1  1.6  1.2 
Na+ (mEq/L)  145  140  136 
K+ (mEq/L)  3.8  4.0  3.6 
Cl (mEq/L)  104  103  101 

pH: negative log of hydrogen ion concentrations: HCO3: bicarbonate; pCO2: partial pressure of carbon dioxide; pO2: partial pressure of oxygen; PT: prothrombin time; PPT: partial thromboplastin time; Na+: sodium; K+: potassium; Cl: chlorine.

Source: Authors.

Pathophysiology of metformin-related lactic acidosis

Metformin is a biguanide and the first drug of choice for blood sugar control in patients with DM type 2 because of its metabolic and cardiovascular benefits.8 The most frequent adverse effects related to its use are gastrointestinal, including nausea, vomiting and diarrhoea. However, the most feared adverse effect is lactic acidosis.7,9 Pyruvate-derived lactate is the end product of glycolysis in anaerobic conditions. Humans produce 1500mmol of lactate per day (0.8mmol/kg/h) in muscle-skeletal tissue (25%), skin (25%), red blood cells (20%), brain (20%) and intestinal tissue (10%). To maintain balance, lactate needs to be removed, and this is done in organs like the liver (60%), kidneys (30%), heart and skeletal muscle (10%).10–12 Any imbalance in the form of increased lactate production, reduced clearance, or both, will give rise to serum lactate elevation (normal <2mmol/L). As a molecule, lactate is found in anion form and not as lactic acid. In the past, it was postulated that in order for lactic acid to occur, the hydrogen ions (H+) required for conversion had to be produced through adenosine triphosphate (ATP) hydrolysis not used in the cytoplasm. Recently, an explanation for the development of acidosis has been postulated on the basis of Stewart's physicochemical theory, according to which pH changes depend on the partial pressure of carbon dioxide (pCO2), the total concentration of non-volatile weak acids, and the strong ion difference (SID), the latter being the cation–anion difference in the extracellular fluid (Na++K++Mg++Ca2+)(Cl+Lactate). This means that an increase in lactate will reduce the SID and, in turn, pH, creating or perpetuating lactic acidosis.13 Traditionally and in accordance with Cohen's classification, lactic acidosis is divided into hypoxaemic type A and non-hypoxaemic type B14,15 (Table 3).

Table 3.

Aetiologic classification of metabolic acidosis.

Classification    Causes 
Type A  Tissue hypoperfusion  Shock (circulatory, septic, cardiogenic and distributive), respiratory failure, anaemia, mesenteric ischaemia, excess exertion. 
Type BB1
Underlying disease 
SIRS, asthma, liver failure, renal failure, malignancy, severe hypophosphatemia, HIV. 
B2
Medications and/or toxic substances 
Metformin, paracetamol, alcohols, adrenergic β2 agonists, salicylates, cyanide, CO, cocaine, retrovirals, propofol, halothane, isoniazid, linezolid, valproic acid, thiamine deficiency, PN. 
B3
Inborn errors of metabolism 
Glucose-6-phosphatase deficiency, fructose-1,6-diphosphatase deficiency, pyruvate carboxilase deficiency, Pearson syndrome 

HIV: human immunodificiency virus; SIRS: systemic inflammatory response syndrome; CO: carbon monoxide; PN: parenteral nutrition.

Source: Authors.

It has been considered that the mechanism for the production of lactic acidosis is multi-factorial: genetic, metabolic oxidation suppression, and Krebs cycle enzyme suppression.16,17 However, the most widely accepted mechanism is the one proposed by Owen,18 whereby metformin affects electron transport, increasing the concentration of reduced nicotinamide adenine dinucleotide or NADH+ and inhibits metabolic oxidation, inducing anaerobic metabolism. Understanding the process of cell respiration is important in order to understand the mechanism through which metformin poisoning causes lactic acidosis type B2. ATP is the “cell's top energy currency”, indispensable for physiological cell function. A process known as cell respiration is required in order to obtain this energy currency in aerobic metabolism. Cell respiration is defined as the generation of energy from nutrient oxidation and it consists of three stages: glycolysis, citric acid cycle (Krebs cycle) and oxidative phosphorilation. Glycolysis consists of a set of enzymatic reactions designed to convert glucose into two pyruvate molecules with energy production (2ATP+2NADH) in the cytoplasm. In order for the Krebs cycle to start, pyruvate needs to enter the mitochondrial matrix and, by the end of the cycle, there will be more metabolic energy (2ATP+8NADH++2FADH2). In the glycolysis and Krebs cycle pathways, energy carriers (NADH+ and FADH2) are derived so that they can be used in oxidative phosphorilation through mitochondrial complexes which play the role of electron mobilisers. This process starts when NADH+ oxidises to NAD+ and gives 2 electrons to complex I; these electrons are transported between complexes II, III, IV and arrive at the mitochondrial matrix in order to bind to an oxygen moiety and 2H+ to form water. Every time electrons travel across complexes, they pump H+ towards the mitochondrial inter-membrane space, creating a proton gradient in complexes I (4H+), III (4H+) and IV (2H+); this gradient is again transported towards the mitochondrial matrix through the ATP synthase complex in order to phosphorilate ADP and produce 4 ATP molecules, resulting in 38 ATPs during the entire cell respiration (2 ATPs are used as currency to initiate glycolysis). In short, the purpose of the three stages of cell respiration is to generate the necessary energy to maintain optimal cell metabolism19–22 (Fig. 1). When, for some reason, the aerobic pathway is not followed, the anaerobic pathway will be activated in order to produce energy. In cases of metformin overdosing, the drug binds to the mitochondrial membranes, specifically complex I, inhibiting the electron transport system (oxidative phosphorilation). When NADH is not oxidised, it accumulates, there is a change in the anaerobic mechanism with increased production of lactate, in an attempt to produce the necessary energy to maintain the physiological conditions of the cell. However, the level of energy is lower and only 4 ATP molecules are produced. Blood lactate accumulates, the SID is altered, and lactic acidosis ensues.

Fig. 1.

Pathophysiology of metformin-related lactic acidosis.

Source: Authors.

(0,62MB).
Discussion

Metformin is a small 165Da molecule with an oral availability of 55% and a distribution volume of 1–5L/kg. It is eliminated practically unchanged through the kidneys, and its total body clearance in subjects with healthy renal function is 500ml/min, 200ml/min with intermittent dialysis, and 50ml/min in patients on slow continuous renal replacement therapy (CRRT). Therapeutic concentrations are 1.5–3.0mg/L. The elimination half-life is 8–20h in individuals with normal renal function.23–28

Outcomes will improve when risk factors for the development of lactic acidosis are recognised, including deterioration of kidney or liver function, alcoholism, reduced tissue perfusion due to infection, age over 60 years, and heart failure in patients receiving metformin-based treatment; also, early diagnosis and timely initiation of renal replacement therapy are critical for success.29,30 The vast majority of patients admitted to the ICU with metformin-related lactic acidosis are over 65 years of age and present with haemodynamic instability and acute renal injury.31 Intermittent or continuous renal replacement therapy with haemodiafiltration to eliminate metformin and lactate from the blood is recommended, the argument being the correlation between reduction of metformin plasma levels and improvement in lactic acidosis.32

Hypotension is treated initially with intravenous fluids, followed by the use of vasopressors if needed. For patients with metformin poisoning, extracorporeal haemodialysis is the preferred treatment as long as there is haemodynamic stability. Although there is limited evidence regarding slow CRRT, it is preferred in patients with haemodynamic instability because it is better tolerated than haemodialysis.33 The working group on extracorporeal treatments in poisoning (EXTRIP), comprised by international experts who represent different societies and specialties, makes recommendations in this regard. Extracorporeal treatment is recommended in severe metformin poisoning (1D), primarily if lactate is ≥15mmol/L, pH ≤7.0 and standard therapy (including NaHCO3) has failed (1D), or in the presence of shock (use of vasopressors) or decline in kidney function (1D). Discontinuation of extracorporeal treatment is indicated when lactate levels are lower than 3mmol/L and pH is higher than 7.35 (1D). Intermittent haemodialysis will always be the first option (1D), although slow CRRT will be the preferred choice in presence of haemodynamic instability (1D).34 Compared to lactic acidosis of a different origin, metformin-related lactic acidosis is associated with lower mortality (50% vs 74%) and has a better prognosis, even when pH is under 7.0.35

On the other hand, treatment of any alteration in acid–base balance must be targeted to the underlying cause. Acidosis has a protective effect in anoxic or ischaemic cells, but that protection will be lost at a certain point, which is still a subject of controversy (pH under 7.2, HCO3 less than 10mEq or base deficit greater than −10mmol/L). Addressing acidosis could result in a paradoxical effect (“harm and no benefit”). Acidosis protection could be related to an enzyme “sparing” effect. Treatment of metabolic acidosis should be aimed at avoiding cell dysfunction occurring as a result of intracellular increase of Na+ and Ca2+ levels, driven by intra and extracellular pH alterations.36

The use of sodium bicarbonate (NaHCO3) is a controversial strategy that has not been fully validated in the clinical scenario of lactic acidosis and haemodynamic instability, regardless of the aetiology. This measure is considered a bridging therapy while waiting for aetiologic treatment. Even the international guidelines of the Surviving Sepsis campaign recommend the use of NaHCO3 when pH is less than or equal to 7.15 in order to improve the haemodynamic state or reduce the number of vasopressors in patients with hypoperfusion-induced lactic acidosis.37 A recent publication of a review study that evaluated the use of NaHCO3 in the treatment of lactic acidosis due to sepsis reported that the routine use of NaHCO3 continues to be controversial, and concluded that further studies are required in order to determine a potential benefit.38 NaHCO3 administration may give rise to side effects, including increased production of carbon dioxide(CO2) and reduced ionised calcium, which may contribute to diminished right ventricular contractility or vascular tone. Moreover, there is the potential for a paradoxical effect because of the improvement in extracellular pH but not so of the intracellular pH (intracellular hypercapnia).39

The use of NaHCO3 in the treatment of metabolic acidosis has been shown to have beneficial effects in diseases where there is evidence of HCO3 loss. In contrast, no benefit has been observed when it has been used to address metabolic acidosis from other causes.40 Additionally, the use of NaHCO3 has been proposed as a diagnostic method in the form of a bicarbonate challenge to determine the origin of metabolic acidosis, mainly in patients with septic shock and severe metabolic acidosis and high risk of hypoperfusion-associated complications such as hypoxic hepatitis, a condition that usually occurs after prolonged hypoperfusion, as well as inflammation, hypoxaemia and hypoxia. It would be wise to assume that prompt and accurate diagnosis of metabolic acidosis (hypoperfusion) will lead to early targeted treatment or help consider a different source (exogenous acid production) at an earlier stage, in order to modify the diagnostic and therapeutic approach.41

We present the management algorithm used in our critical care unit in cases of lactic acidosis (Fig. 2).

Fig. 2.

Algorithm for the diagnosis and treatment of lactic acidosis.

NaHCO3: sodium bicarbonate; pH: negative log of hydrogen ion concentrations; PaCO2: carbon dioxide arterial pressure; ΔCO2: carbon dioxide difference; ΔCO2/ΔavO2: carbon dioxide difference between arterio-venous oxygen difference; MAP: mean arterial pressure; SvcO2: central venous oxygen saturation; SpO2: peripheral oxygen saturation; Hb: haemoglobin; VO2: oxygen consumption; CVP: central venous pressure; RRT: renal replacement therapy.

Source: Author.

(0,64MB).
Conclusion

Lactic acidosis is common in critically ill patients and correlates with severity and prognosis. However, the aetiology of lactic acidosis is a key determining factor for outcome. Timely diagnosis of the mechanism and cause of lactic acidosis will favour early targeted treatment. Treatment success depends on the control of the aetiologic source. Metformin-related lactic acidosis has a better prognosis lactic acidosis induced by septic shock. Intermittent or continuous renal replacement therapy should be used as the first step in the treatment of metformin-related lactic acidosis.

Ethical disclosuresProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data

The authors declare that no patient data appears in this article.

Right to privacy and informed consent

The authors declare that no patient data appears in this article.

Funding

The authors were not sponsored to carry out this article

Conflict of interest

The authors declare not having received external funding for this research and not having conflict of interest regarding publication.

Acknowledgement

We thank the medical and nursing team on the different work schedules in the intensive care unit who collaborated in the comprehensive care.

References
[1]
R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, et al.
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.
Crit Care Med, 41 (2013), pp. 580-637
[2]
C.G. Morris, J. Low.
Metabolic acidosis in the critically ill: part 1. Classification and pathophysiology.
Anaesthesia, 63 (2008), pp. 294-301
[3]
J.A. Kraut, I. Kurtz.
Use of base in the treatment of acute severe organic acidosis by nephrologists and critical care physicians: results of an online survey.
Clin Exp Nephrol, 10 (2006), pp. 111-117
[4]
D.T. Noritomi, F.G. Soriano, J.A. Kellum, S.B. Cappi, P.J. Biselli, A.B. Liborio, et al.
Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study.
Crit Care Med, 37 (2009), pp. 2733-2739
[5]
I. Smith, P. Kumar, S. Molloy, A. Rhodes, P.J. Newman, R.M. Grounds, et al.
Base excess and lactate as prognostic indicators for patients admitted to intensive care.
Intensive Care Med, 27 (2001), pp. 74-83
[6]
D. Kirpichnikov, S.I. McFarlane, J.R. Sowers.
Metformin: an update.
Ann Intern Med, 137 (2002), pp. 25-33
[7]
A. Seidowsky, S. Nseir, N. Houdret, F. Fourrier.
Metformin-associated lactic acidosis: a prognostic and therapeutic study.
Crit Care Med, 37 (2009), pp. 2191-2196
[8]
R. Roussel, F. Travert, B. Pasquet, P.W. Wilson, S.C. Smith Jr., S. Goto, et al.
Metformin use and mortality among patients with diabetes and atherothrombosis.
Arch Intern Med, 170 (2010), pp. 1892-1899
[9]
S. Friesecke, P. Abel, M. Roser, S.F. Felix, S. Runge.
Outcome of severe lactic acidosis associated with metformin accumulation.
Crit Care, 14 (2010), pp. R226
[10]
C. Vernon, J.L. Le Tourneau.
Lactic acidosis: recognition, kinetics, and associated prognosis.
Crit Care Clin, 26 (2010), pp. 255-283
[11]
A.J. Reddy, S.W. Lam, S.R. Bauer, J.A. Guzman.
Lactic acidosis: clinical implications and management strategies.
Cleve Clin J Med, 82 (2015), pp. 615-624
[12]
J. Seheult, G. Fitzpatrick, G. Boran.
Lactic acidosis: an update.
Clin Chem Lab Med, 55 (2017), pp. 322-333
[13]
J.S. Sánchez-Díaz, C. Meneses-Olguín, E. Monares-Zepeda, A. Torres-Gómez, J. Aguirre-Sánchez, J. Franco-Granillo.
La diferencia de iones fuertes (DIF) calculada por el método de Fencl-Stewart simplificado es un predictor de mortalidad en pacientes con choque séptico.
Arch Med Urgen México, 6 (2014), pp. 5-11
[14]
R.D. Cohen, H.F. Woods.
The clinical presentation and classification of lactic acidosis.
Clinical and biochemical aspects of lactic acidosis,
[15]
J.P. Ruiz, A.K. Singh, P. Hart, B. Type.
lactic acidosis secondary to malignancy: case report, review of published cases, insights into pathogenesis, and prospects for therapy.
Sci World J, 11 (2011), pp. 1316-1324
[16]
P.W. Caton, N.K. Nayuni, J. Kieswich, N.Q. Khan, M.M. Yaqoob, R. Corder.
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.
J Endocrinol, 205 (2010), pp. 97-106
[17]
X.M. Leverve, B. Guigas, D. Detaille, C. Batandier, E.A. Koceir, C. Chauvin, et al.
Mitochondrial metabolism and type-2 diabetes: a specific target of metformin.
Diabetes Metab, 29 (2003),
6S88–94
[18]
M.R. Owen, E. Doran, A.P. Halestrap.
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J, 348 (2000), pp. 607-614
[19]
A. Luengo, L.B. Sullivan, M.G. Vander Heiden.
Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy.
[20]
J. Bakker, M.W. Nijsten, T.C. Jancen.
Clinical use of lactate monitoring in critically ill patients.
Ann Intensive Care, 3 (2013), pp. 12
[21]
G. Rena, E.R. Pearson, K. Sakamoto.
Molecular mechanism of action of metformin: old or new insight?.
Diabetologia, 56 (2013), pp. 1898-1906
[22]
J. Zheng, S.L. Woo, X. Hu, R. Botchlett, L. Chen, Y. Huo, et al.
Metformin and metabolic diseases: a focus on hepatic aspects.
Front Med, 9 (2015), pp. 173-186
[23]
G.G. Graham, J. Punt, M. Arora, R.O. Day, M.P. Doogue, J.K. Duong, et al.
Clinical pharmacokinetics of metformin.
Clin Pharmacokinet, 50 (2011), pp. 81-98
[24]
J.D. Lalau, C. Lacroix.
Measurement of metformin concentration in erythrocytes: clinical implications.
Diabetes Obes Metab, 5 (2003), pp. 93-98
[25]
C.R. Sirtori, G. Franceschini, M. Galli-Kienle, G. Cighetti, G. Galli, Bondioli, et al.
Disposition of metformin (N,N-dimethylbiguanide) in man.
Clin Pharmacol Ther, 24 (1978), pp. 683-693
[26]
A.J. Scheen.
Clinical pharmacokinetics of metformin.
Clin Pharmacokinet, 30 (1996), pp. 359-371
[27]
P.J. Pentikäinen, P.J. Neuvonen, A. Penttilä.
Pharmacokinetics of metformin after intravenous and oral administration to man.
Eur J Clin Pharmacol, 16 (1979), pp. 195-202
[28]
J.D. Lalau, M. Andrejak, P. Morinière, B. Coevoet, X. Debussche, P.F. Westeel, et al.
Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination.
Int J Clin Pharmacol Ther Toxicol, 27 (1989), pp. 285-288
[29]
M.J. Kim, J.Y. Han, J.Y. Shin, S.I. Kim, J.M. Lee, S. Hong, et al.
Metformin-associated lactic acidosis: predisposing factors and outcome.
Endocrinol Metab, 30 (2015), pp. 78-83
[30]
J.D. Lalau.
Lactic acidosis induced by metformin.
[31]
N. Peters, N. Jay, D. Barraud, A. Cravoisy, L. Nace, P.E. Bollaert, et al.
Metformin-associated lactic acidosis in an intensive care unit.
Crit Care, 12 (2008), pp. R149
[32]
R. De Fronzo, G.A. Fleming, K. Chen, T.A. Bicsak.
Metformin-associated lactic acidosis: current perspectives on causes and risk.
Metabolism, 65 (2016), pp. 20-29
[33]
P. Alivanis, I. Giannikouris, C. Paliuras, A. Arvanitis, M. Volanaki, A. Zervos.
Metformin-associated lactic acidosis treated with continuous renal replacement therapy.
[34]
D.P. Calello, K.D. Liu, T.J. Wiegand, D.M. Roberts, V. Lavergne, S. Gosselin, et al.
Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the extracorporeal treatments in poisoning workgroup.
Crit Care Med, 43 (2015), pp. 1716-1730
[35]
S. Friesecke, Abel Peter, Roser Markus, S.B. Felix, S. Runge.
Outcome of severe lactic acidosis associated with metformin accumulation.
Crit Care, 14 (2010), pp. R226
[36]
J.S. Sánchez-Díaz, E.A. Martínez-Rodríguez, L.P. Méndez-Rubio, K.G. Peniche-Moguel, J.M. Huanca-Pacaje, C. López-Guzmán, et al.
Equilibrio ácido-base. Puesta al día. Teoría de Henderson-Hasselbalch.
Med Int Méx, 32 (2016), pp. 646-660
[37]
A. Rhodes, L.E. Evans, W. Alhazzani, M.M. Levy, M. Antonelli, R. Ferrer, et al.
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.
Intensive Care Med, 43 (2017), pp. 304-377
[38]
D. Velissaris, V. Karamouzos, N. Ktenopoulos, C. Pierrakos, M. Karanikolas.
The use of sodium bicarbonate in the treatment of acidosis in sepsis: a literature update on a long term debate.
Crit Care Res Pract, 2015 (2015), pp. 605830
[39]
C.G. Morris, J. Low.
Metabolic acidosis in the critically ill: part 2. Causes and treatment.
Anaesthesia, 63 (2008), pp. 396-411
[40]
M.M. Adeva-Andany, C. Fernández-Fernández, D. Mouriño-Bayolo, E. Castro-Quintela, A. Domínguez-Montero.
Sodium bicarbonate therapy in patients with metabolic acidosis.
Sci World J, (2014),
627673
[41]
M.G.A. Palazzo.
Sodium bicarbonate – the bicarbonate challenge test in metabolic acidosis: a practical consideration.
Curr Anaesth Crit Care, 20 (2009), pp. 259-263

Please cite this article as: Sánchez-Díaz JS, Monares-Zepeda E, Martínez-Rodríguez EA, Cortés-Román JS, Torres-Aguilar O, Peniche-Moguel KG, et al. Acidosis láctica por metformina: reporte de caso. Rev Colomb Anestesiol. 2017;45:353–359.

Copyright © 2017. Sociedad Colombiana de Anestesiología y Reanimación
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.